Čájehuvvojit 1 - 8 oktiibuot 8 bohtosis ohcui "Pharmacokinetics and pharmacodynamics"', ohcanáigi: 0,02s Aiddostahte ozu
  1. 1
    Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

    Supplementary Figure S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cance... Dahkki Aurelius Omlin (14971513)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer

    Supplementary Table S1 from Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer Dahkki Aurelius Omlin (14971513)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates

    Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates Dahkki Evan C. Chen (15054014)

    Almmustuhtton 2025
    Fáttát:
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: